SCHEMBL1543035

SCHEMBL1543035

COc1c(C(=O)Nc2ccc(CNS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.61
NR1H4 Q96RI1 3/20 0.44
ABL1 P00519 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MAPK1 P28482 1/20 0.38
BCL2 P10415 1/20 0.37
INSR P06213 1/20 0.37
ALK Q9UM73 1/20 0.37
MAPT P10636 4/20 0.36
GAA P10253 2/20 0.36
ALDH1A1 P00352 1/20 0.36
RECQL P46063 1/20 0.36
TRPV1 Q8NER1 2/20 0.36
NFATC1 O95644 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 1/20 0.36
NAMPT P43490 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542760 0.92 CYP3A4 (0.55) CYP3A4NR1H4ABL1KDM4EMAPT
SCHEMBL1542666 0.86 CYP3A4 (0.56) CYP3A4NR1H4ABL1KDM4EBCL2
SCHEMBL1542824 0.85 CYP3A4 (0.52) CYP3A4NR1H4ABL1KDM4EMAPT
SCHEMBL2128170 0.84 CYP3A4 (0.53) CYP3A4NR1H4ABL1KDM4EMAPK1
SCHEMBL1542683 0.83 CYP3A4 (0.61) CYP3A4NR1H4ABL1KDM4EMAPK1
SCHEMBL1542466 0.83 CYP3A4 (0.54) CYP3A4NR1H4KDM4ERECQLNFATC1
SCHEMBL2127583 0.82 CYP3A4 (0.50) CYP3A4NR1H4ABL1KDM4EMAPK1
SCHEMBL1542874 0.81 CYP3A4 (0.51) CYP3A4NR1H4ABL1KDM4EMAPT
SCHEMBL1542202 0.81 CYP3A4 (0.60) CYP3A4ABL1KDM4EMAPK1MAPT
SCHEMBL1542187 0.80 CYP3A4 (0.49) CYP3A4NR1H4ABL1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885NR1H4 658/4885ABL1 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.